Edition:
United States

Proteostasis Therapeutics Inc (PTI.OQ)

PTI.OQ on NASDAQ Stock Exchange Global Market

2.90USD
16 Feb 2018
Change (% chg)

$-0.21 (-6.75%)
Prev Close
$3.11
Open
$3.14
Day's High
$3.14
Day's Low
$2.86
Volume
91,280
Avg. Vol
254,450
52-wk High
$16.65
52-wk Low
$1.41

Chart for

About

Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant... (more)

Overall

Beta: --
Market Cap(Mil.): $96.03
Shares Outstanding(Mil.): 33.11
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Proteostasis Therapeutics Prices Public Offering Of 8 Mln Shares At $5/Share

* PROTEOSTASIS THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK

Dec 13 2017

BRIEF-Proteostasis Therapeutics Announces Positive Clinical Results From Cystic FibrosisStudies

* PROTEOSTASIS THERAPEUTICS ANNOUNCES POSITIVE CLINICAL RESULTS FROM STUDIES OF PTI-428, PTI-801 AND PTI-808 IN HEALTHY VOLUNTEERS AND PATIENTS WITH CYSTIC FIBROSIS

Dec 11 2017

BRIEF-Proteostasis Therapeutics Q3 loss per share $0.56

* Proteostasis Therapeutics reports third quarter 2017 results and provides CF portfolio update

Nov 14 2017

BRIEF-Proteostasis Therapeutics to prioritize resources on cystic fibrosis R&D

* Proteostasis Therapeutics - ‍initiated strategic prioritization to focus resources on research & development of cystic fibrosis programs, among others​

Oct 31 2017

Earnings vs. Estimates